News coverage about Opiant Pharmaceuticals (NASDAQ:OPNT) has been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Opiant Pharmaceuticals earned a news impact score of 0.07 on Accern’s scale. Accern also assigned news coverage about the technology company an impact score of 48.546351738533 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
A number of equities research analysts recently weighed in on OPNT shares. TheStreet raised shares of Opiant Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Monday, October 16th. ValuEngine cut shares of Opiant Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, October 2nd.
Shares of Opiant Pharmaceuticals (NASDAQ:OPNT) traded down $0.32 on Tuesday, reaching $24.11. 18,400 shares of the company were exchanged, compared to its average volume of 32,140. Opiant Pharmaceuticals has a 52-week low of $5.00 and a 52-week high of $51.90. The stock has a market capitalization of $48.55, a PE ratio of 57.40 and a beta of -0.28.
In other news, major shareholder Geoffrey Wolf sold 2,570 shares of the company’s stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $30.40, for a total value of $78,128.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 63.82% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Opiant Pharmaceuticals (OPNT) Stock Price” was originally reported by Markets Daily and is owned by of Markets Daily. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.themarketsdaily.com/2018/01/09/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-opiant-pharmaceuticals-opnt-stock-price.html.
Opiant Pharmaceuticals Company Profile
Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.